8-K
filed February 20, 2024, 6:59 PM ET
ticker MD
CIK 0000893949
earnings
confidence high
sentiment negative
materiality 0.75
Pediatrix Q4 GAAP loss $1.50/share; adj EPS $0.32; 2024 EBITDA guidance $200-220M
Pediatrix Medical Group, Inc.
2023-FY EPS reported
$0.73
revenue$1,994,640,000
- GAAP diluted loss from continuing ops $1.50 vs income $0.29 a year ago; $168.3M non-cash impairment.
- Adj EPS $0.32 (down from $0.47); net revenue $496M (-3.4% YoY); same-unit revenue -1.5%.
- Q4 adjusted EBITDA $50.8M (vs $66.5M); full-year adj EBITDA $200.4M (vs $241M).
- Preliminary 2024 adj EBITDA guidance $200-220M, roughly flat to down from 2023.
- Net AR $272.3M; total debt $628M; no revolver borrowings; cash from ops $72.1M.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Pediatrix Medical Group, Inc. reported the year ended December 31, 2023 results: revenue $1.99 billion.
- Period
- the year ended December 31, 2023
- Revenue
- $1.99 billion
- Result
- reported results
Exact text from the filing
For the year ended December 31, 2023, Pediatrix generated revenue from continuing operations of $1.99 billion, compared to $1.97 billion for the prior year.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Pediatrix Medical Group, Inc. reported the three months ended December 31, 2023 results: revenue $496 million, net income Loss from continuing operations of $124 million, EPS loss from continuing operations of $1.50 per diluted share.
- Period
- the three months ended December 31, 2023
- Revenue
- $496 million
- Net income
- Loss from continuing operations of $124 million
- EPS
- loss from continuing operations of $1.50 per diluted share
- Result
- reported results
Exact text from the filing
For the 2023 fourth quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $496 million; • Loss from continuing operations of $124 million; and • Adjusted EBITDA of $51 million.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.